New Oncotarget publication: EntreChem's mithralog EC-8042 targets sarcoma cancer stem cells by inhibiting SP1 transcription factor
May 2nd, 2016 - Oviedo (Spain)
The results of a collaborative research from EntreChem SL and the Hospital Universitario Central de Asturias, HUCA (Oviedo, Spain), focused on a new strategy for treating sarcomas, especially targeting the tumor initiating cells…
|
EntreChem's mithralog EC-8042 promising activity for Ewing sarcoma,
published in Clinical Cancer Research
April 4th, 2016 - Oviedo (Spain)
The research, directed by Patrick Grohar, Ph.D. M.D. screened a panel of mithralogs to establish their ability to inhibit EWS-FLI1 in Ewing sarcoma cell line. Both mithramycin and EC-8042 suppress the activity of EWS-FLI1…
|
EntreChem's orally active EC-70124 reverts tumorigenic
and stem cell properties in prostate cancer
March 10th, 2016 - Oviedo (Spain)
The research, directed by Dr. Carlo Catapano (IOR), focuses on the frequently activated STAT3 and NF-kB transcription factors and their blocking by the multi-kinase inhibitor EC-70124…
|
more news & media |
|
|
